Fast, hungry and unstable: finding the Achilles' heel of small-cell lung cancer

Christine Hann, Charles M. Rudin

Research output: Contribution to journalArticle

Abstract

Over 95% of patients with small-cell lung cancer (SCLC) die within five years of diagnosis. The standard of care and the dismal prognosis for this disease have not changed significantly over the past 25 years. Some of the characteristics of SCLC that have defined it as a particularly virulent form of cancer - rapid proliferation, excessive metabolic and angiogenic dependence, apoptotic imbalance and genetic instability - are now being pursued as tumor-specific targets for intervention both in preclinical and early phase clinical studies. Here, we summarize areas of ongoing anti-cancer drug development, including classes of agents that target essential pathways regulating proliferation, angiogenesis, apoptotic resistance, chromosomal and protein stability, and cell-cell and cell-matrix interaction.

Original languageEnglish (US)
Pages (from-to)150-157
Number of pages8
JournalTrends in Molecular Medicine
Volume13
Issue number4
DOIs
StatePublished - Apr 2007

Fingerprint

Small Cell Lung Carcinoma
Neoplasms
Chromosomal Instability
Protein Stability
Standard of Care
Cell Communication
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Fast, hungry and unstable : finding the Achilles' heel of small-cell lung cancer. / Hann, Christine; Rudin, Charles M.

In: Trends in Molecular Medicine, Vol. 13, No. 4, 04.2007, p. 150-157.

Research output: Contribution to journalArticle

@article{2a211341734b48a4ab996e7d35579f11,
title = "Fast, hungry and unstable: finding the Achilles' heel of small-cell lung cancer",
abstract = "Over 95{\%} of patients with small-cell lung cancer (SCLC) die within five years of diagnosis. The standard of care and the dismal prognosis for this disease have not changed significantly over the past 25 years. Some of the characteristics of SCLC that have defined it as a particularly virulent form of cancer - rapid proliferation, excessive metabolic and angiogenic dependence, apoptotic imbalance and genetic instability - are now being pursued as tumor-specific targets for intervention both in preclinical and early phase clinical studies. Here, we summarize areas of ongoing anti-cancer drug development, including classes of agents that target essential pathways regulating proliferation, angiogenesis, apoptotic resistance, chromosomal and protein stability, and cell-cell and cell-matrix interaction.",
author = "Christine Hann and Rudin, {Charles M.}",
year = "2007",
month = "4",
doi = "10.1016/j.molmed.2007.02.003",
language = "English (US)",
volume = "13",
pages = "150--157",
journal = "Trends in Molecular Medicine",
issn = "1471-4914",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Fast, hungry and unstable

T2 - finding the Achilles' heel of small-cell lung cancer

AU - Hann, Christine

AU - Rudin, Charles M.

PY - 2007/4

Y1 - 2007/4

N2 - Over 95% of patients with small-cell lung cancer (SCLC) die within five years of diagnosis. The standard of care and the dismal prognosis for this disease have not changed significantly over the past 25 years. Some of the characteristics of SCLC that have defined it as a particularly virulent form of cancer - rapid proliferation, excessive metabolic and angiogenic dependence, apoptotic imbalance and genetic instability - are now being pursued as tumor-specific targets for intervention both in preclinical and early phase clinical studies. Here, we summarize areas of ongoing anti-cancer drug development, including classes of agents that target essential pathways regulating proliferation, angiogenesis, apoptotic resistance, chromosomal and protein stability, and cell-cell and cell-matrix interaction.

AB - Over 95% of patients with small-cell lung cancer (SCLC) die within five years of diagnosis. The standard of care and the dismal prognosis for this disease have not changed significantly over the past 25 years. Some of the characteristics of SCLC that have defined it as a particularly virulent form of cancer - rapid proliferation, excessive metabolic and angiogenic dependence, apoptotic imbalance and genetic instability - are now being pursued as tumor-specific targets for intervention both in preclinical and early phase clinical studies. Here, we summarize areas of ongoing anti-cancer drug development, including classes of agents that target essential pathways regulating proliferation, angiogenesis, apoptotic resistance, chromosomal and protein stability, and cell-cell and cell-matrix interaction.

UR - http://www.scopus.com/inward/record.url?scp=33947632458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947632458&partnerID=8YFLogxK

U2 - 10.1016/j.molmed.2007.02.003

DO - 10.1016/j.molmed.2007.02.003

M3 - Article

C2 - 17324626

AN - SCOPUS:33947632458

VL - 13

SP - 150

EP - 157

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

SN - 1471-4914

IS - 4

ER -